by Lori Solomon The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults. The oral medication represents the first new class of medicine in several decades and selectively targets M1 and M4 receptors in the brain, without blocking D2 receptors. The approval is...
Tag: <span>Schizophrenia</span>
Post
Psychedelic use linked to increased risk of schizophrenia, study finds
Peer-Reviewed Publication Institute for Clinical Evaluative Sciences image: Infographic: Myran et al. JAMA Psych. 2024view more Credit: ICES Ottawa, ON, November 13, 2024 – Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, according to a new study from researchers at ICES, The Ottawa Hospital, University of Ottawa’s Department of Family...
Post
Scientists may have found the reason why people with schizophrenia hear voices
Insights from new research could help expand treatment options beyond drugs Schizophrenia is a poorly understood illness, but scientists now have greater insight into one of the disorder’s hallmarks, auditory hallucinations, thanks to new research published Thursday. People with schizophrenia often “hear” voices and sounds even when there are none — up to 80% of...
Post
How does schizophrenia affect smell?
Scientists believe schizophrenia may affect a person’s sense of smell or cause them to smell things that are not there, but not all studies into schizophrenia and smell support this. Schizophrenia is a mental health condition that affects how a person thinks, feels, and behaves. The condition may also affect a person’s sense of smell...
Post
IS A NEW SCHIZOPHRENIA DRUG REALLY A GAME CHANGER?
A new drug is being hailed as a breakthrough for the 2.8 million American adults (among 24 million people worldwide) who battle schizophrenia. The US Food & Drug Administration (FDA) has greenlit Bristol Myers Squibb’s Cobenfy, reportedly making it the first major new treatment for the disorder in 70 years. Unlike other antipsychotic drugs, Cobenfy appears to...
Post
Scientists may have found the reason why people with schizophrenia hear voices
People with schizophrenia often “hear” voices and sounds even when there are none — up to 80% of people with the mental illness have auditory hallucinations. Scientists have theorized that this happens when a person with schizophrenia struggles to recognize inner speech as self-generated. But nobody had been able to fully explain the mechanisms behind this...
Post
High BMI during childhood linked to increased risk of schizophrenia in adulthood
September 17, 2024 by Bob Yirka , Medical Xpress Scatter plots of SNP potential effects on childhood and adulthood BMI versus significantly associated outcomes in the Psychiatric Genomics Consortium dataset. BMI, body mass index. A, adulthood BMI versus major depressive disorder; B, adulthood BMI versus schizophrenia; C, adulthood BMI versus obsessive-compulsive disorder; D, childhood BMI...
Post
Severe side effects of the most effective schizophrenia medication identified
September 18, 2024 by University of Helsinki Credit: Pixabay/Gerd AltmannAbout one-third of patients with schizophrenia do not respond to conventional medications, leaving them with one effective treatment option: clozapine. Clozapine’s most serious side effect, a life-threatening drop in white blood cell levels, has been effectively controlled through strict monitoring. However, recent findings show that the...
Post
Unraveling schizophrenia: New insights into genetic and environmental interplay
September 10, 2024 by Genomic Press Credit: Pixabay/CC0 Public DomainIn the complex landscape of mental health research, a new viewpoint offers a critical examination of how genes and environment conspire to influence schizophrenia risk. Published in Genomic Psychiatry, this analysis by researchers Natassia Robinson and Sarah E. Bergen from Karolinska Institutet in Stockholm, Sweden, brings...
Post
Researchers discover a mechanism that impairs synaptic plasticity in the brains of schizophrenia patients
News Release 4-Sep-2024 Peer-Reviewed PublicationTampere University A new study led by researchers at Tampere University has mapped genes linked to schizophrenia and uncovered a mechanism that disrupts synaptic plasticity in affected individuals. The researchers showed the role of three proteins in mediating the impairments of plasticity in schizophrenia. The findings may hold promise for the...